BRPI0015061B8 - comprimido revestido tendo alta dosagem de cloridrato de sevelamer - Google Patents

comprimido revestido tendo alta dosagem de cloridrato de sevelamer

Info

Publication number
BRPI0015061B8
BRPI0015061B8 BRPI0015061A BR0015061A BRPI0015061B8 BR PI0015061 B8 BRPI0015061 B8 BR PI0015061B8 BR PI0015061 A BRPI0015061 A BR PI0015061A BR 0015061 A BR0015061 A BR 0015061A BR PI0015061 B8 BRPI0015061 B8 BR PI0015061B8
Authority
BR
Brazil
Prior art keywords
tablet core
aliphatic amine
amine polymer
polymer
weight
Prior art date
Application number
BRPI0015061A
Other languages
English (en)
Other versions
BRPI0015061B1 (pt
BR0015061A (pt
Inventor
S Petersen John
Tyler Joseph
Original Assignee
Geltex Pharma Inc
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geltex Pharma Inc, Genzyme Corp filed Critical Geltex Pharma Inc
Publication of BR0015061A publication Critical patent/BR0015061A/pt
Publication of BRPI0015061B1 publication Critical patent/BRPI0015061B1/pt
Publication of BRPI0015061B8 publication Critical patent/BRPI0015061B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"núcleo de comprimido de polímero por compressão direta". a presente invenção provê um núcleo de comprimido que compreende pelo menos cerca de 95% em peso de um polímero de amina alifática. a invenção também provê um método para produzir um núcleo de comprimido compreendendo pelo menos cerca de 95% em peso de uma resina de polímero de amina alifática. o método compreende a etapa de comprimir o polímero de amina alifática para formar o núcleo de comprimido. o núcleo de comprimido pode adicionalmente incluir um ou mais excipientes. nesta configuração, o método para produzir o núcleo de comprimido compreende as etapas de: (1) hidratar o polímero de amina alifática até o nível de umidade desejado; (2) misturar o polímero de amina alifática com os excipientes em quantidades tais que o polímero compreenda pelo menos cerca de 95% em peso da mistura resultante; e (3) comprimir a mistura para formar o núcleo de comprimido. a presente invenção adicionalmente relaciona-se com um comprimido revestido compreendendo um núcleo de polímero de amina alifática onde o revestimento é um revestimento baseado em água.
BRPI0015061A 1999-10-19 2000-10-13 comprimido revestido tendo alta dosagem de cloridrato de sevelamer BRPI0015061B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16025899P 1999-10-19 1999-10-19
US17422700P 2000-01-03 2000-01-03
PCT/US2000/028548 WO2001028527A2 (en) 1999-10-19 2000-10-13 Direct compression polymer tablet core

Publications (3)

Publication Number Publication Date
BR0015061A BR0015061A (pt) 2002-07-23
BRPI0015061B1 BRPI0015061B1 (pt) 2016-03-22
BRPI0015061B8 true BRPI0015061B8 (pt) 2021-05-25

Family

ID=26856737

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0015061A BRPI0015061B8 (pt) 1999-10-19 2000-10-13 comprimido revestido tendo alta dosagem de cloridrato de sevelamer

Country Status (29)

Country Link
EP (1) EP1239837B1 (pt)
JP (4) JP4942271B2 (pt)
KR (1) KR100794427B1 (pt)
CN (1) CN1202812C (pt)
AR (1) AR026067A1 (pt)
AT (1) ATE286386T1 (pt)
AU (1) AU778262B2 (pt)
BG (1) BG106626A (pt)
BR (1) BRPI0015061B8 (pt)
CA (1) CA2387915C (pt)
CZ (1) CZ20021344A3 (pt)
DE (1) DE60017285T2 (pt)
EA (1) EA200200387A1 (pt)
EE (1) EE200200209A (pt)
ES (1) ES2235969T3 (pt)
HK (1) HK1049451B (pt)
HU (1) HUP0203334A2 (pt)
IL (1) IL149146A0 (pt)
IS (1) IS6343A (pt)
MX (1) MXPA02003684A (pt)
MY (1) MY125495A (pt)
NO (1) NO20021827L (pt)
NZ (1) NZ518334A (pt)
PL (1) PL364888A1 (pt)
PT (1) PT1239837E (pt)
SK (1) SK5412002A3 (pt)
TR (1) TR200201087T2 (pt)
TW (1) TWI225413B (pt)
WO (1) WO2001028527A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1202812C (zh) * 1999-10-19 2005-05-25 基酶有限公司 直接压缩聚合物片剂核
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7767768B2 (en) 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
WO2005065291A2 (en) * 2003-12-31 2005-07-21 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
DE602005018619D1 (de) 2004-03-30 2010-02-11 Relypsa Inc Ionenbindende zusammensetzungen
AU2012200480B2 (en) * 2004-11-01 2014-10-16 Genzyme Corporation "Aliphatic amine polymer salts for tableting"
US7985418B2 (en) * 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
AU2006227429A1 (en) * 2005-03-17 2006-09-28 Amgen Inc. Methods of decreasing calcification
CA2620406A1 (en) 2005-09-02 2007-03-08 Genzyme Corporation Method for removing phosphate and polymer used therefore
ES2556217T3 (es) * 2005-09-15 2016-01-14 Genzyme Corporation Formulación en bolsa para polímeros de amina
EP2441779A1 (en) * 2006-09-01 2012-04-18 USV Limited Process for the preparation of sevelamer hydrochloride and formulation thereof
JP2010504975A (ja) 2006-09-29 2010-02-18 ゲンズイメ コーポレーション アミドデンドリマー組成物
JP2010513271A (ja) 2006-12-14 2010-04-30 ゲンズイメ コーポレーション アミド−アミンポリマー組成物
WO2009034540A1 (en) * 2007-09-11 2009-03-19 Ranbaxy Laboratories Limited Pharmaceutical composition of sevelamer
DE102008030046A1 (de) * 2008-06-25 2009-12-31 Ratiopharm Gmbh Kompaktiertes Polyallylamin-Polymer
WO2010041268A2 (en) 2008-09-02 2010-04-15 Usv Limited Crosslinked polymers
US20100330175A1 (en) * 2009-06-24 2010-12-30 Jobdevairakkam Christopher N Cross-linked polyallylamine tablet core
WO2010149794A2 (en) * 2009-06-26 2010-12-29 Combino Pharm, S.L. Novel pharmaceutical composition comprising poly (allylamin-co-n,n'-diallyl- 1,3-diamino-2-hydroxypropane)
ES2350999B1 (es) * 2009-06-26 2011-12-07 Combino Pharm, S.L. Nueva composición farmacéutica comprendiendo hidrocloruro de poli (alilamin-co-n,n'-dialil-1,3-diamino-2-hidroxi propano).
ES2720869T3 (es) * 2009-10-22 2019-07-25 Synthon Bv Composiciones farmacéuticas de sevelámero
EP2545907A1 (en) 2011-07-15 2013-01-16 Combino Pharm, S.L. Aqueous wet granulation process for cross-linked polyallylamine polymers
US9693962B2 (en) * 2012-06-05 2017-07-04 Takeda Pharmaceutical Limited Dry-coated tablet
CN102908325B (zh) * 2012-11-12 2014-07-30 南京生命能科技开发有限公司 一种碳酸司维拉姆药用片剂组合物及其制备方法
CN107412166B (zh) * 2017-08-08 2020-03-24 同济大学 一种纳米复合吸附磷材料及其制备与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222242B1 (hu) * 1991-07-03 2003-05-28 Pharmacia & Upjohn Co. Kolesztipol-hidroklorid tabletta és eljárás annak előállítására
US5496545A (en) * 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
JP3389493B2 (ja) * 1997-04-04 2003-03-24 中外製薬株式会社 リン酸結合性ポリマー製剤
TW592727B (en) * 1997-04-04 2004-06-21 Chugai Pharmaceutical Co Ltd Phosphate-binding polymer preparations
US6083497A (en) * 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
TW568788B (en) * 1998-10-12 2004-01-01 Chugai Pharmaceutical Co Ltd Polymer combining with phosphoric acid and preparation containing the same
CN1202812C (zh) * 1999-10-19 2005-05-25 基酶有限公司 直接压缩聚合物片剂核

Also Published As

Publication number Publication date
TR200201087T2 (tr) 2002-08-21
TWI225413B (en) 2004-12-21
CA2387915C (en) 2007-04-17
HUP0203334A2 (hu) 2003-02-28
KR20020059629A (ko) 2002-07-13
CA2387915A1 (en) 2001-04-26
NO20021827L (no) 2002-05-29
MY125495A (en) 2006-08-30
EP1239837A2 (en) 2002-09-18
JP2003512317A (ja) 2003-04-02
NZ518334A (en) 2003-08-29
EE200200209A (et) 2003-06-16
EA200200387A1 (ru) 2002-10-31
ES2235969T3 (es) 2005-07-16
IS6343A (is) 2002-04-15
DE60017285D1 (de) 2005-02-10
AR026067A1 (es) 2002-12-26
HK1049451B (zh) 2005-12-16
ATE286386T1 (de) 2005-01-15
EP1239837B1 (en) 2005-01-05
BRPI0015061B1 (pt) 2016-03-22
MXPA02003684A (es) 2002-08-30
BR0015061A (pt) 2002-07-23
PL364888A1 (en) 2004-12-27
NO20021827D0 (no) 2002-04-18
KR100794427B1 (ko) 2008-01-16
JP2014065749A (ja) 2014-04-17
CN1382041A (zh) 2002-11-27
AU1088701A (en) 2001-04-30
JP2012067132A (ja) 2012-04-05
JP2016000753A (ja) 2016-01-07
BG106626A (bg) 2003-03-31
SK5412002A3 (en) 2002-09-10
JP5903111B2 (ja) 2016-04-13
DE60017285T2 (de) 2005-12-08
HK1049451A1 (en) 2003-05-16
IL149146A0 (en) 2002-11-10
CZ20021344A3 (cs) 2002-08-14
JP4942271B2 (ja) 2012-05-30
WO2001028527A3 (en) 2002-01-03
CN1202812C (zh) 2005-05-25
PT1239837E (pt) 2005-05-31
WO2001028527A2 (en) 2001-04-26
AU778262B2 (en) 2004-11-25
JP5583110B2 (ja) 2014-09-03

Similar Documents

Publication Publication Date Title
BRPI0015061B8 (pt) comprimido revestido tendo alta dosagem de cloridrato de sevelamer
BRPI0316532B8 (pt) composições farmacêuticas compreendendo uma droga básica ou ácida, um tensoativo, e um ácido ou base solúvel em água fisiologicamente tolerável
MXPA05001061A (es) Composiciones farmaceuticas, acuosas de 2,6-diisopropilfenol.
DE122004000032I2 (de) Zusammensetzung die eine Tramadol-Verbindung und Acetaminophen enth{lt, und ihre Verwendung
BR0013720A (pt) Formulação em pelota de liberação controlada
IT1288290B1 (it) Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
BR9714739A (pt) Composição farmacêutica para reduzir a depressão respiratória e os efeitos colaterais inerentes de compostos opióides mu
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
BR0113608A (pt) Composição cosmética clara em emulsão antiperspirante e/ou desodorante
ATE489099T1 (de) Aminozucker, chondroitin und s-adenosylmethionin enthaltende zusammensetzungen
BR0109150A (pt) Método para administração de um anestésico local a um indivìduo em necessidade de um efeito anestésico local, emplastro, composição, e, recipiente
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
BR9806801A (pt) Utilização de um antagonista de receptores cb1, composição farmacêutica, e, estojo para o tratamento de distúrbios da apetência
NO964213D0 (no) Forbedret anti-flass shampo
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
KR930005617A (ko) 트라마돌 및 코데인, 옥시코돈 또는 하이드로코돈을 함유하는 조성물 및 그의 용도
BR9913400A (pt) Formulação oral de liberação imediata na forma sólida de um inibidor de trombina, uso de um inibidor de trombina baseado em peptìdeo de baixo peso molecular, processos para a profilaxia e/ou o tratamento de trombo-embolismo, e para a preparação de uma formulação oral de liberação imediata, e, uso de uma carga escolhida do grupo consistindo de um derivado de celulose, e um derivado de amido
ATE375729T1 (de) Verfahren zur herstellung eines pharmazeutischen kaugummis
HK1084015A1 (en) Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3- carboxylic acid derivatives 2-
BR0107371A (pt) Formulação de inìcio rápido
BR9814764A (pt) Composição aquosa, uso da mesma, e, substrato.
RS4204A (en) Dosage regimen and pharmaceutical composition for emergency contraception
BR0207827A (pt) Método de preparação de uma micropartìcula homogênea que compreende um inibidor de h+/k+-atpase ácido lábil, micropartìcula, composição farmacêutica, método para prevenir ou tratar uma doença relacionada com o ácido gástrico em um mamìfero, e, uso de uma micropartìcula
BR0107958A (pt) Composição farmacêutica contendo pemetrexado juntamente com l-cisteìna monotrioglicerol ou ácido tioglicólico
BR9914155A (pt) Composições curáveis de revestimento contendo combinações de compostos funcionais de carbamato

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: GENZYME CORPORATION (US)

Free format text: TRANSFERIDO DE: GELTEX PHARMACEUTICALS, INC.

B25G Requested change of headquarter approved

Owner name: GENZYME CORPORATION (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 018080029522/SP DE 14/05/2008.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 9/20

Ipc: A61K 31/785 (2009.01), A61K 9/28 (2009.01), A61K 3

B15V Prolongation of time limit allowed

Free format text: DEVOLUCAO DE PRAZO CONCEDIDA - RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 19 DIAS, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/03/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/10/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 13/10/2020